Pyrimidine derivative used as Wee1 inhibitor

A technology of drugs and compounds, applied in the field of anti-tumor drug preparation, can solve the problems of cell apoptosis and DNA damage that cannot be repaired

Inactive Publication Date: 2021-03-05
WIGEN BIOMEDICINE TECH SHANGHAI CO LTD
View PDF15 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Inhibit checkpoint function, DNA damage cannot be repaired, and cells undergo apoptosis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pyrimidine derivative used as Wee1 inhibitor
  • Pyrimidine derivative used as Wee1 inhibitor
  • Pyrimidine derivative used as Wee1 inhibitor

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0062] Example 1: Compound 1

[0063]

[0064] synthetic route:

[0065]

[0066] Step 1: Synthesis of compound 1-1

[0067] Dissolve tert-butyl 3-hydroxymethylpiperazine-1-carboxylate (1.0 g, 4.63 mmol) and 1,2-difluoro-4-nitrobenzene (809 mg, 5.1 mmol) in DMF (20 mL), add DIPEA (1.8g, 13.89mmol), heated up to 120°C and reacted overnight. After the reaction was monitored by LC-MS, water (100mL) was added to the reaction system, extracted with EA (50mL*2), the organic phase was combined, and the organic phase was washed with saturated saline ( 50mL) washed with anhydrous Na 2 SO 4 After drying, the filtrate was concentrated and the residue was subjected to column chromatography (PE / EA=10 / 1to 5 / 1) to obtain a yellow solid compound (600 mg, yield 60%), ESI-MS m / z: 356.1 [M+H] + .

[0068] Step 2: Synthesis of Compound 1-2

[0069] Compound 1-1 ((3.6g, 10mmol) was dissolved in DMF (30mL), ice bathed, NaH (60% content, 440mg, 11mmol) was added, and the temperature was ...

Embodiment 2

[0081] Example 2: Compound 2

[0082]

[0083] synthetic route:

[0084]

[0085] Step 1: Synthesis of Compound 2-1

[0086] Dissolve compound 1-3 (706mg, 3.0mmol) in 1,2-dichloroethane (20mL), add acetone (1mL), AcOH (180mg, 3.0mmol), r.t.stir for 1h, add NaBH(OAc) 3 (1.26g, 6mmol), r.t. reacted overnight, LC-MS monitored the completion of the reaction, concentrated, the residue was dissolved in EA (30mL), saturated NaHCO 3 solution (30mL), washed with anhydrous Na 2 SO 4 After drying, the filtrate was concentrated, and the residue was subjected to column chromatography (DCM / MeOH=100 / 1 to 20 / 1) to obtain a yellow solid (400 g, yield 48%), ESI-MS m / z: 278.1 [M+H] + .

[0087] Step 2: Synthesis of compound 2-2

[0088] Compound 2-1 (400mg, 1.44mmol) was dissolved in MeOH (30mL), Pd / C (10%, 80mg) was added, and H 2 , r.t. reacted overnight, LC-MS monitored after the reaction was completed, filtered, and the filtrate was concentrated to obtain a light yellow solid co...

Embodiment 3

[0092] Example 3: Compound 3

[0093]

[0094] Using oxetane and compound 1-3 as raw materials, compound 3 was obtained by using a synthesis method similar to that of Example 2.

[0095] 1 H NMR (400MHz, DMSO-d 6)δ:9.98(s,1H),8.76(s,1H),7.94(t,J=7.9Hz,1H),7.72(d,J=8.1Hz,1H),7.58(dd,J=7.7,0.9 Hz,1H),7.15(d,J=9.3Hz,2H),6.79(d,J=8.9Hz,1H),5.67-5.56(m,1H),5.28(s,1H),4.81-4.73(m ,3H),4.64-4.48(m,4H),4.22(d,J=10.5Hz,1H),3.87-3.70(m,2H),3.64(d,J=11.6Hz,1H),2.96(t, J=9.9Hz, 1H), 2.79(d, J=10.9Hz, 2H), 2.63-2.50(m, 2H), 2.09-2.00(m, 1H), 1.70-1.60(m, 1H), 1.43(s ,6H); ESI-MS m / z:571.2[M+H] + .

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a pyrimidine derivative used as a Weel inhibitor. The invention relates to a novel compound shown as a formula (1A) or a formula (1B) and / or pharmaceutically acceptable salt thereof, a composition containing the compound shown as the formula (1A) or the formula (1B) and / or pharmaceutically acceptable salt thereof, a preparation method and application of the compound servingas a Wee1 inhibitor in preparation of antitumor drugs.

Description

technical field [0001] The invention belongs to the field of medicinal chemistry, and more specifically relates to a new compound with Weel kinase inhibitory effect, a preparation method thereof and the use of the compound in the preparation of antitumor drugs. Background technique [0002] Wee-1 protein kinase is an important negative regulatory protein in cell cycle checkpoints. Cell cycle checkpoints include the G1 phase checkpoint for the transition from G1 (cell resting phase) to the S phase (DNA synthesis phase), the G2 phase checkpoint for the transition from G2 (cell division preparation phase) to the M (cell division phase) phase, and the M The spindle checkpoint for the metaphase (middle phase of cell division) to anaphase (late phase of cell division) transition. Wee-1 protein kinase plays an important role in the G2 phase checkpoint. The entry of cells into the M phase depends on the activity of CDK1 kinase. Wee-1 inhibits the activity of CDK1 by phosphorylatin...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C07D519/00A61K31/5383A61K31/519A61P35/00A61P35/02
CPCC07D519/00A61P35/00A61P35/02A61K31/519A61K31/5383C07D487/04C07D487/14C07D471/14
Inventor 樊后兴谢雨礼
Owner WIGEN BIOMEDICINE TECH SHANGHAI CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap